The Challenge of Treating Children with Hepatitis C Virus Infection

Journal of Pediatric Gastroenterology and Nutrition

Volumn 64, Issue 6, 2017, Pages 851-854

  Indolfi, Giuseppe ^a   Thorne, Claire ^b   El Sayed, Manal H ^c   Giaquinto, Carlo ^d,e   Gonzalez Peralta, Regino P ^f  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d UNIVERSITY OF PADOVA   (Italy)

^e Intl Maternal Pediatric Adolescent AIDS Clinical Trials   (Italy)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

chronic viral hepatitis; direct Acting antiviral therapy; hepatitis C virus; pediatric hepatology; pediatric liver disease

Indexed keywords

ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; INTERFERON; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; RIBAVIRIN; URIDINE PHOSPHATE;

ANTIVIRAL THERAPY; ARTICLE; CHILD HEALTH CARE; HEPATITIS C; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; PRIORITY JOURNAL; THERAPY DELAY; ADOLESCENT; ANALOGS AND DERIVATIVES; CHILD; CHRONIC HEPATITIS C; COMBINATION DRUG THERAPY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CHILD; DRUG THERAPY, COMBINATION; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; INTERFERON TYPE I; RIBAVIRIN; URIDINE MONOPHOSPHATE;

EID: 85016628327     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000001589     Document Type: Article

References (32)

1. Choo QL, Kuo G, Weiner AJ, et al. Isolation of ac DNA clone derived from blood borne non-A, non-B viral hepatitis genome. Science 1989;294:359-62.
2. Chung RT, Baumert TF. Curing chronic hepatitis C: The arc of medical triumph. N Engl J Med 2014;370:1576-8.
3. Schaefer EAK, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012;142:1340-50.
4. Messina JP, Humphreys I, Flaxsman A, et al. Global distribution and prevalence of hepatitis C virus genotype. Hepatology 2015;61:77-87.
5. Rein DB, Wittenborn IS, Weinbaum CM, et al. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66-72.
6. Gower F, Estes CC, Hindeman S, et al. Global epidemiology and genotype distribution for the hepatitis C virus infection. J Hepatol 2014:545-57.
7. El-Shabrawi MH, Kamal NM. Burden of pediatric hepatitis C. World J Gastroenterol 2013;19:7880-8.
8. http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/. Accessed July 2016.
9. American Association for Ne Study of Liver Disease. HCV Guidance: Recommendations for testing, managing and treating hepatitis C. www.hcvguidelines.org/full-report-view. Accessed December 2016.
10. European Association for the study of Liver. Clinical March Guidelines: Recommendation on treatment of hepatitis C 2015. www.easl.eu/research/our-contributions/clinicalpractice-guidelines/detail/recommen dations-on-Treatment-of-hepatitis-c-2015. Accessed May 5, 2015.
11. Vargas HE. Hepatitis C treatment in 2016. Reason to be an optimist. Hepatology 2016;64:330-1.
12. Lewib E, Mangea A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
13. Sulkowski MS, Gardner DF, Rodriguez-Torres VM, et al. DacIatasvir plus sofosbuvir for previously treated and untreated chronic HCV infection. N Engl J Med 2014;370:211-21.
14. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment naive patients: The COSMOS randomised trial. Lancet 2014;384:1756-65.
15. Kwo P, Gitlin N, Nahass R, et al. Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1 infected patients without cirrhosis: OPTIMIST-1, a phase 3, randomized study. Hepatology 2016;64:370-80.
16. Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST-2). Hepatology 2016;64:360-9.
17. Feld JJ, Jacobson C, Hezode T, et al. Sofosbuvir and Velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015;373:2599-607.
18. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015;373:2608-17.
19. Sulkowski MS, Vargas HE, Di BisceglieAM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patientswith HCV genotype 1 infection. Gastroenterology 2016;150:419-29.
20. Pol S, Bourliere M, Lucier S, et al. Safety and efficacy of the combination daclatasvir sofosbuvir in HCV genotype 1-mono-infected patients from the French Observational cohort ANRS CO22. J Hepatol 2015;62:S258.
21. Backus LI, Belperio PS, Shahoumian TA, et al. Effectiveness of sofosbuvir-based regimens in genotype 1 and 2 hepatitis C virus infection in 4026 U.S. Veterans. Aliment Pharmacol Ther 2015;42:559-73.
22. Druyts E, Thorlund K, Wu P, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: A systematic review and metaanalysis. Clin Infect Dis 2013;56:961-7.
23. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology 2011;140:450.e1-8.e1.
24. Wirth S, Ribes-Koninckx C, Calzado MA, et al. High sustained virologic response rates in children with chronic hepatitis C receiving peginterferon alfa-2b plus ribavirin. J Hepatol 2010;52:501-7.
25. Schwarz KB, Molleston JP, Jonas MM, et al. Children treated with pegylated interferon alfa-2a ribavirin for chronic hepatitis C. J Peds Gastroenterol Nutr 2016;62:93-6.
26. Balistreri WF, Murray KF, Rosenthal P, et al. The safety and effectiveness of Ledipasvir-Sofosbuvir in adolescents 12 to 17 years old with hepatitis C virus genotype 1 infection. Hepatology 2016 [Epub ahead of print].
27. Schwarz K, Rosenthal P, Gonzalez-Peralta RP, et al. Hepatology 2016;64:349A.
28. Pho MT, Linas BP. Valuing cure: fast affections and coverage decrements for hepatitis C therapy. Hepatology 2014;60:12-3.
29. Bortolotti F, Verucci G, Camma C, et al. Long-Term course of chronic hepatitis C in children: from viral clearance to end-stage liver disease. Gastroenterology 2008;134:1900-7.
30. Zoulim F, Liang TJ, Gerbes AL, et al. Hepatitis C virus treatment in the real world: optimizing treatment and access to therapies. Gut 2015;64: 1824-33.
31. www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/events/2014/12/event-detail-001074.jsp&mid=WC0b01ac058004d5c3. Accessed July 2016.
32. http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/docu ments/document/ucm 225333.pdf. Accessed July 2016.